SLRX: Multiplikator P/S Salarius
The absence of commercial products leaves Salarius Pharmaceuticals (SLRX) dependent on venture capital investments. The current P/S valuation on the GURU.Markets terminal illustrates a chart of the metric, where the value 20.40 represents the most recent figure. Business stability is supported by the non-cyclical nature of oncology, while trial safety is guaranteed by strict adherence to the cold chain during component transportation.
Rincian analitis perusahaan Salarius (SLRX)
- rega lan prakiraan konsensus rega:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Rasio Kabeh Utang marang Dana Pribadi Salarius Pharmaceuticals|SLRX - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal Salarius Pharma|SLRX - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Salarius|SLRX - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Salarius Pharmaceuticals|Rasio jangkoan perantara salariuspharma.com
- rincian asil keuangan lan kelipatan valuasi:
SLRX - Bathi resik perusahaan|Bathi forward Salarius Pharmaceuticals|SLRX - Pangali P/E|Pangali mangsa ngarep rega marang bathi Salarius Pharmaceuticals Inc|SLRX - Pangali PEG|Pangali EV/EBITDA Salarius|SLRX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Salarius Pharmaceuticals|SLRX - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan salariuspharma.com|SLRX - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Salarius Pharmaceuticals
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:SLRX salariuspharma.com
The P/S ratio correlates the market capitalization of Salarius Pharmaceuticals (SLRX) with its revenue, revealing valuation premiums relative to operational efficiency. Analyzing the company's historical P/S value helps identify capital correction risks in the absence of sales growth, which is critical for assessing the expansion potential of Ewing sarcoma drugs and solid tumor therapies within oncology centers.
Pesaing Salarius Pharmaceuticals
Koefisien rega marang pendapatan beigene.com|Multiplikator P/S HALO (Halozyme)|Multiplikator P/S Revolution Medicines Inc RVMD|AAPG - Rasio rega marang pendapatan|CGON: Rasio rega marang pendapatan|URGN: Multiplikator P/S|bicara.com (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan Personalis|ERAS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DCTH|Koefisien rega marang pendapatan Y-mAbs Corp|Aura Biosciences, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S Candel Therapeutics Inc. CADL|ARAY - Rasio rega marang pendapatan|Koefisien rega marang pendapatan SELLAS Life Sciences SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Citius Oncology Inc - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan TuHURA Biosciences Inc.|protaratx.com - Rasio rega marang dodolan|Multiplikator P/S FATE|WHWK (aadibio.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S TCRX (TScan Therapeutics, Inc.)|Multiplikator P/S Champions Oncology Inc CSBR|XBIT - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CVM (CEL-SCI Corporation)|OS Therapies (OSTX) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan radiopharmtheranostics.com|ARTV (Artiva Biotherapeutics Inc.) - Multiplikator P/S|Multiplikator P/S Adlai Nortye Limited|Multiplikator P/S VERU|Kapitalisasi marang pendapatan tempesttx.com TPST|Multiplikator P/S XLO (Xilio Therapeutics)|Renovaro Biosciences (RENB) - Rega marang dodolan|MURA: Kapitalisasi marang pendapatan|KAPA - Multiplikator P/S|OKUR (onkuretherapeutics.com) - Kapitalisasi marang pendapatan|GDTC: Kapitalisasi marang volume dodolan|CRIS (Curis Inc.) - Multiplikator P/S|Apollomics Corp (APLM) - Koefisien rega marang pendapatan|Multiplikator P/S THAR|Kapitalisasi marang pendapatan advanbiomed.com ADVB|Multiplikator P/S GNPX (Genprex, Inc.)|Multiplikator P/S Calidi Biotherapeutics Inc. CLDI|SBFM - Rasio rega marang pendapatan|XBIO: Rasio rega marang pendapatan|Purple Biotech Corp (PPBT) - Rasio rega marang pendapatan|AONC - Koefisien rega marang pendapatan|Rasio rega marang pendapatan BeiGene, Ltd.|checkpointtx.com (CKPT) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Elevation Oncology (ELEV)|Rasio rega marang pendapatan ICAD (icadmed.com)|Rasio rega marang pendapatan Ikena Oncology IKNA|Rasio kapitalisasi pasar marang pendapatan NTBL|VIRX: Kapitalisasi marang pendapatan|MOR (morphosys.com) - Rasio kapitalisasi marang pendapatan|NAYA: Multiplikator P/S|Kapitalisasi marang pendapatan Ascentage Pharma Group International
